What is the pathophysiology of diabetic ketoacidosis (DKA) and euglycemic diabetic ketoacidosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Pathophysiology of DKA and Euglycemic DKA

Both classic DKA and euglycemic DKA share the same fundamental metabolic derangement—insulin deficiency coupled with counterregulatory hormone excess driving ketogenesis—but differ critically in their glucose handling, with euglycemic DKA maintaining near-normal glucose levels (typically <200-250 mg/dL) due to preserved urinary glucose excretion or carbohydrate deficit states.

Classic Diabetic Ketoacidosis (DKA)

Core Hormonal Derangement

The pathophysiology centers on reduced net effective insulin action combined with elevated counterregulatory hormones (glucagon, catecholamines, cortisol, and growth hormone) 1. This hormonal imbalance triggers a cascade of metabolic consequences:

Glucose metabolism disruption:

  • Increased hepatic and renal glucose production
  • Impaired peripheral glucose utilization
  • Results in marked hyperglycemia (typically >250 mg/dL)
  • Parallel increases in extracellular osmolality 1

Ketone body production:

  • Insulin deficiency plus counterregulatory hormone excess stimulates adipose tissue lipolysis
  • Free fatty acids released into circulation
  • Unrestrained hepatic fatty acid oxidation produces ketone bodies (β-hydroxybutyrate and acetoacetate)
  • Accumulation causes ketonemia and metabolic acidosis 1, 2

Fluid and electrolyte losses:

  • Hyperglycemia-induced glycosuria drives osmotic diuresis
  • Progressive loss of water, sodium, potassium, and other electrolytes
  • Leads to profound dehydration and electrolyte depletion 1

Clinical Evolution

DKA typically evolves rapidly, within 24 hours in most cases, though occasionally develops more acutely without warning 1. The mortality rate is approximately 5% in experienced centers, worsening significantly with extremes of age, coma, or hypotension 1.

Euglycemic Diabetic Ketoacidosis

Distinguishing Pathophysiology

Euglycemic DKA represents a diagnostic challenge because it presents with the metabolic acidosis and ketosis of DKA but without the expected severe hyperglycemia 3, 4. The key pathophysiologic difference involves:

Carbohydrate deficit state:

  • Relative or absolute carbohydrate deficit despite insulin deficiency
  • Milder degree of insulin deficiency or resistance compared to classic DKA
  • Increased glucagon/insulin ratio still drives ketogenesis 5
  • Enhanced urinary glucose excretion prevents hyperglycemia accumulation 4

Preserved glucose excretion mechanisms:

  • SGLT2 inhibitors are the most common modern precipitant, causing obligatory glucosuria that prevents glucose accumulation despite ketogenesis 6, 7
  • The drug-induced carbohydrate deficit signals cellular fuel shortage, triggering the same counterregulatory hormone response as classic DKA 6
  • Metabolic shift from glucose to lipid utilization drives ketone body production 6

Additional Precipitating Contexts

Beyond SGLT2 inhibitors, euglycemic DKA occurs in specific clinical scenarios where glucose availability is limited 4, 5:

  • Starvation states (reduced oral intake, fasting)
  • Pregnancy (increased metabolic demands, insulin resistance)
  • Chronic liver disease (impaired gluconeogenesis)
  • Alcohol use (depleted glycogen stores, impaired gluconeogenesis)
  • Bariatric surgery (reduced carbohydrate absorption)
  • Insulin pump failure (in context of reduced carbohydrate intake)

Diagnostic Criteria Distinction

Euglycemic DKA is defined by 4, 5:

  • Serum glucose **<200-250 mg/dL** (versus >250 mg/dL in classic DKA)
  • Anion gap metabolic acidosis
  • Ketonemia/ketonuria
  • pH typically <7.3 with low bicarbonate

Critical Clinical Pitfall

The absence of marked hyperglycemia in euglycemic DKA frequently delays diagnosis, as clinicians may not suspect DKA when glucose is near-normal 3, 5. This diagnostic delay worsens outcomes. The condition requires high clinical suspicion in diabetic patients presenting with:

  • Non-specific GI symptoms (nausea, vomiting)
  • Malaise or fatigue
  • Known SGLT2 inhibitor use
  • Recent starvation, illness, surgery, or pregnancy 7

Always check serum or urine ketones in diabetic patients with metabolic acidosis regardless of glucose level 7. Blood ketone meters significantly improve diagnostic accuracy and speed.

Shared Final Common Pathway

Despite the glucose difference, both conditions produce the same life-threatening metabolic acidosis through ketone body accumulation 2. The reduction in insulin-glucagon ratio signals cellular fuel shortage, promoting lipolysis and hepatic β-oxidation of fatty acids, yielding acetyl-CoA that converts to ketone bodies 2. This fundamental mechanism explains why treatment principles remain similar—both require insulin to suppress ketogenesis, though euglycemic DKA requires concurrent dextrose administration to prevent hypoglycemia during insulin therapy 4, 5.

References

Guideline

hyperglycemic crises in diabetes.

Diabetes Care, 2004

Research

Pathophysiology of Ketoacidosis: Core Curriculum 2026.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2026

Research

Euglycemic Diabetic Ketoacidosis: How Is It Different from Diabetic Ketoacidosis.

Critical care nursing clinics of North America, 2025

Research

Euglycemic diabetic ketoacidosis: Etiologies, evaluation, and management.

The American journal of emergency medicine, 2021

Research

Euglycemic diabetic ketoacidosis: A missed diagnosis.

World journal of diabetes, 2021

Research

Euglycemic Diabetic Ketoacidosis: Clinical Suspicion and Diagnosis.

Clinical medicine insights. Endocrinology and diabetes, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.